AC Immune director Pfeifer proposes $56K share sale
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
AC Immune SA director and officer Andrea M.A. Pfeifer gave notice of a proposed sale of 20,000 common shares, with an aggregate market value of $56,000.00 and an approximate sale date of May 15, 2026. Her Rule 10b5-1 plan adoption date is March 27, 2025.
Pfeifer states the shares were acquired upon vesting of previously exercised stock options between June 1, 2012 and May 11, 2016. She also reports three earlier Rule 10b5-1 sales: 10,000 shares on February 17, March 16 and April 15, 2026, for gross proceeds of $28,693.00, $31,966.00 and $31,425.00, respectively.
Key Figures
Key Terms
Rule 10b5-1 regulatory
Previously Exercised Stock Options financial
Aggregate Market Value financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What recent ACIU sales did Andrea M.A. Pfeifer report?
AI-generated analysis. How Rhea-AI works. Not financial advice.